Who Paid My Doc
Evanthia Galanis
Medical Oncology Rochester, MN Medical Doctor
NPI 1326028234 CMS profile 286517
200 1St St Sw, Rochester, MN 55905
General payments
$22,684
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$72,239,556
Through program year 2024, Evanthia Galanis of Rochester, MN is reported in the CMS Open Payments database as having received $22,684 across 10 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $72,239,556 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 74th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $20,259 | 8 | |
| 2020 | General | $2,425 | 2 |
Beside peers
- Evanthia Galanis
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Evanthia Galanis were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Evanthia Galanis | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $968 | $140–$6,658 | $163 |
| 2020 | $2,425 | $747 | $102–$5,891 | $114 |
| 2021 | $0 | $430 | $50–$4,098 | $132 |
| 2022 | $0 | $812 | $127–$4,907 | $149 |
| 2023 | $0 | $957 | $144–$5,248 | $160 |
| 2024 | $20,259 | $1,042 | $149–$5,650 | $164 |
| 2025 | $0 | $1,128 | $147–$5,675 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 108 billing codesPaid by Medicare
$1,080,219
Medicare patients
241
Services billed
46,324
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 64% | |
| Cancer | 48% | |
| Arthritis | 30% | |
| Diabetes | 29% | |
| Chronic kidney disease | 29% | |
| Ischemic heart disease | 21% | |
| Depression | 17% | |
| Osteoporosis | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 34 | 7,800 | $349,132 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 12 | 2,521 | $91,789 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 11 | 60 | $8,251 |
| Injection, bortezomib (velcade), 0.1 mg J9041 | Office | 12 | 770 | $1,068 |
| Injection, carboplatin, 50 mg J9045 | Office | 29 | 235 | $660 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 31 | 5,100 | $568 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 53 | 570 | $424 |
| Injection, fluorouracil, 500 mg J9190 | Office | 17 | 156 | $377 |
| Injection, paclitaxel, 1 mg J9267 | Office | 24 | 4,450 | $367 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 14 | 50 | $180 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
10 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Medical Oncology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.